Annual Information Update
18 July 2008 - 4:01PM
UK Regulatory
RNS Number : 3265Z
Celsis International PLC
18 July 2008
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Annual Information update
18 July 2008: Celsis International plc, the international life sciences products and laboratory services company, is pleased to provide
an annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has
been published or made available by the Company to the public over the twelve months preceding this announcement. To avoid a statement of
unnecessary length information is referred to in this update rather than included in full.
In accordance with Rule 5.2.7 of the Prospectus Rules, the information referred to in this update was up to date at the time the
information was published but some information may now be out of date. This annual information update does not constitute an offer of
securities addressed to any person and should not be relied on by any person.
1. Announcements made via the Regulatory News Service ("RNS"), a Regulatory Information Service ("RIS").
Date of Publication Regulatory Headline
3 July 2008 Annual Report and Accounts
18 June 2008 Final Results
2 June 2008 Notice of Results
28 May 2008 Holding(s) in Company
24 April 2008 Holding(s) in Company
7 April 2008 Holding(s) in Company
7 April 2008 Holding(s) in Company
27 March 2008 Agreement
27 March 2008 Pre Close Trading Update
7 February 2008 Interim Management Statement
5 February 2008 Holding(s) in Company
16 January 2008 Director/PDMR Shareholding
7 January 2008 Holding(s) in Company
7 January 2008 Holding(s) in Company
3 January 2008 Holding(s) in Company
2 January 2008 Holding(s) in Company
20 December 2007 Holding(s) in Company
31 October 2007 Interim Results
9 October 2007 Notice of Results
27 September 2007 Pre Close Trading Update
24 September 2007 Holding(s) in Company
7 September 2007 Holding(s) in Company
29 August 2007 Director/PDMR Shareholding
14 August 2007 Interim Management Statement
31 July 2007 Director/PDMR Shareholding
26 July 2007 AGM Result
26 July 2007 AGM Statement
18 July 2007 Annual Information Update
Copies of all announcements can be obtained from the Regulatory News Service of the London Stock Exchange.
2. Documents filed at Companies House
The documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated. Copies of
these documents can be obtained from Companies House.
Date Document type Description
26 September 2007 AA Report and Accounts
11 September 2007 363 Annual Return
21 August 2007 288b Director Resigned
24 July 2007 287 Registered office change
3. Documents sent to Shareholders
The documents listed below have been despatched by the Company to holders of its securities on or around the following dates.
Date Description
30 June 2008 2008 Annual Report and Accounts
30 June 2008 Notice of Annual General Meeting
14 May 2008 Deemed Consent Letter
5 December 2007 2007 Interim Report
4. Documents submitted to the UK Listing Authority
Copies of the following documents have been submitted to the UK Listing Authority for inspection at their Document Viewing Facility on
or around the following dates and can be obtained from the Company Secretary, Celsis International plc, 1010 Cambourne Business Park,
Cambourne, Cambridge, CB23 6DP.
Date Description
30 June 2008 2008 Annual Report and Accounts
30 June 2008 Notice of Annual General Meeting
5 December 2007 2007 Interim Report
Enquiries:
Celsis International plc Tel: +44 (0) 1223 598 428
Christian Madrolle, Company Secretary
Jenny Woolway, Corporate Communications
Financial Dynamics Tel: +44 (0) 20 7831 3113
David Yates
Jonathan Birt
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the
pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its
customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's
leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and
consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide
significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its
comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry
and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing
products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug
discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly
metabolised by the human liver.
Further information can be found on its website at www.celsis.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AIUZDLFFVDBBBBX
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024
